Project Brief

A biotech company is pioneering new approaches in oncology through Targeted Protein Degradation (TPD). TPD represents a next-generation therapeutic modality designed not just to inhibit but to eliminate disease-causing proteins. Within TPD, modalities are gaining traction:

• PROTACs (Proteolysis-Targeting Chimeras)

• Molecular glue degraders, which induce protein–protein interactions to trigger degradation.

Molecular glues are particularly attractive due to their smaller size, drug-like properties, and clinical precedent (e.g., thalidomide derivatives).

Overview of the Technology

Developed an AI-driven discovery platform that integrates binding pattern recognition and ternary complex modeling to identify novel molecular glue degraders. By combining predictive modeling with experimental validation, the platform accelerates degrader discovery and improves success rates.

Positioning itself as both a drug discovery innovator and a strategic partner, the company is advancing its own oncology pipeline while offering its platform for licensing and collaboration.

VentureBlick is conducting a preliminary study to help the company assess its global potential.

Selected advisors will not be identified individually – only their country and specialty will be noted. All insights will remain confidential and proprietary to the client.

Expert Profiles

Medical Experts

• Practicing specialists with 5+ years’ experience managing HCC and/or NSCLC.

• Familiarity with AI-driven drug discovery or novel modalities (TPD, molecular glues, PROTACs).

• Ability to discuss treatment practices, unmet needs, and the potential role of new modalities (e.g., TPDs).

Industry Experts

• Biopharma or CRO professionals with 10+ years’ experience in oncology drug development (pre-clinical or clinical).

• Familiarity with AI-driven drug discovery or novel modalities (TPD, molecular glues, PROTACs).

• Experience in licensing/partnership evaluations or investment decision-making highly valued.

Work Required

• Review: Read a detailed backgrounder on the company and its activities (1 hour)

• Survey: Complete a structured questionnaire providing insights based on your expertise in oncology, drug development, AI in drug discovery, or commercialization pathways.

Note

If your expertise aligns with this project, we encourage you to apply for consideration. Due to expected high interest, only shortlisted advisors will be contacted for follow-ups.

For specific questions regarding eligibility or other inquiries, please reach out via the contact details below.